← Back to Search

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Phase 1
Waitlist Available
Led By Frank Lee
Research Sponsored by Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new drug in healthy adults. It will help identify possible side effects and measure how the drug behaves in the body.

Eligible Conditions
  • Lymphoma
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single dose of DZD8586Experimental Treatment1 Intervention
Single dose of DZD8586
Group II: Single dose of PlaceboPlacebo Group1 Intervention
Single dose of Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD8586
2021
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dizal (Jiangsu) Pharmaceutical Co., Ltd.Lead Sponsor
2 Previous Clinical Trials
200 Total Patients Enrolled
Frank LeePrincipal InvestigatorFrontage Clinical Services, Inc.
1 Previous Clinical Trials
15 Total Patients Enrolled
~16 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top